Profile data is unavailable for this security.
About the company
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
- Revenue in USD (TTM)682.00k
- Net income in USD-201.59m
- Incorporated2018
- Employees452.00
- LocationPhathom Pharmaceuticals Inc100 Campus Drive, Suite 102FLORHAM PARK 07932United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.phathompharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nkarta Inc | 0.00 | -117.50m | 551.70m | 150.00 | -- | 1.41 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Korro Bio Inc | 0.00 | -81.17m | 555.92m | 101.00 | -- | 3.27 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| OmniAB Inc | 34.16m | -50.62m | 559.86m | 106.00 | -- | 1.78 | -- | 16.39 | -0.4986 | -0.4986 | 0.3292 | 2.69 | 0.0858 | -- | 2.00 | 322,301.90 | -12.71 | -- | -13.55 | -- | -- | -- | -148.16 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Verve Therapeutics Inc | 11.76m | -200.07m | 563.59m | 255.00 | -- | 0.9216 | -- | 47.93 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| GH Research PLC | 0.00 | -35.59m | 571.79m | 49.00 | -- | 2.61 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 682.00k | -201.59m | 573.54m | 452.00 | -- | -- | -- | 840.96 | -3.89 | -3.89 | 0.0133 | -1.26 | 0.0024 | -- | -- | 1,508.85 | -69.68 | -83.26 | -78.50 | -93.77 | 75.51 | -- | -29,558.94 | -135,982.00 | 10.22 | -4.91 | 1.20 | -- | -- | -- | -1.96 | -- | -- | -- |
| AnaptysBio Inc | 17.16m | -163.62m | 574.60m | 117.00 | -- | 6.48 | -- | 33.49 | -6.07 | -6.07 | 0.6372 | 3.31 | 0.0323 | -- | 4.15 | 146,641.00 | -30.79 | -18.08 | -32.75 | -18.96 | -- | -- | -953.66 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Astria Therapeutics Inc | 0.00 | -72.89m | 579.23m | 59.00 | -- | 2.93 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -118.46m | 582.96m | 186.00 | -- | 2.34 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Wave Life Sciences Ltd | 113.31m | -57.51m | 585.74m | 266.00 | -- | 14.40 | -- | 5.17 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 591.30m | 234.00 | -- | 3.61 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 593.51m | 232.00 | -- | 1.16 | -- | 6,247.50 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Mineralys Therapeutics Inc | 0.00 | -71.90m | 595.57m | 28.00 | -- | 2.05 | -- | -- | -1.79 | -1.79 | 0.00 | 5.86 | 0.00 | -- | -- | 0.00 | -39.28 | -- | -41.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.93m | -64.37m | 596.29m | 25.00 | -- | -- | -- | 308.64 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 596.42m | 181.00 | -- | 1.41 | -- | 9.39 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Data as of Apr 17 2024. Currency figures normalised to Phathom Pharmaceuticals Inc's reporting currency: US Dollar USD
28.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 31 Dec 2023 | 2.88m | 4.93% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.38m | 4.08% |
| Ensign Peak Advisors, Inc.as of 31 Dec 2023 | 2.28m | 3.90% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.90m | 3.25% |
| Avidity Partners Management LPas of 31 Dec 2023 | 1.72m | 2.94% |
| Gilder, Gagnon, Howe & Co. LLCas of 31 Dec 2023 | 1.46m | 2.49% |
| 683 Capital Management LLCas of 31 Dec 2023 | 1.28m | 2.19% |
| Woodline Partners LPas of 31 Dec 2023 | 1.10m | 1.87% |
| Geode Capital Management LLCas of 31 Dec 2023 | 735.27k | 1.26% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 687.84k | 1.18% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
